Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23203945 | 0.95 | ALDH1A1 (0.33) | KDM4EMEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL21862741 | 0.94 | ALDH1A1 (0.32) | KDM4EMEN1ALDH1A1TP53CYP1A2 | |
| SCHEMBL24574977 | 0.94 | KDM4E (0.32) | HCRTR1KDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL25975507 | 0.94 | KDM4E (0.32) | HCRTR1KDM4EALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL21863023 | 0.93 | PTGER4 (0.31) | KDM4EALDH1A1TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL26415822 | 0.93 | PTGER4 (0.31) | KDM4EALDH1A1TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL21863024 | 0.93 | PTGER4 (0.32) | KDM4EALDH1A1TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL21862823 | 0.92 | TUBB4A (0.32) | — | |
| SCHEMBL23204107 | 0.92 | PTGER4 (0.34) | KDM4EALDH1A1TP53SMN1; SMN2HSD17B10 | |
| SCHEMBL23468864 | 0.92 | PTGER4 (0.32) | HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128360-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE | LT MATERIALS CO., LTD. (KR) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128360-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME, COMPOSITION FOR ORGANIC LAYER OF ORGANIC LIGHT EMITTING DEVICE | CRY1, ORC3, ODC1 | HCRTR1 540/4885KDM4E 3080/4885MEN1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.